CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 2.36 HKD 2.61%
Market Cap: 3B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CStone Pharmaceuticals
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Accounts Receivables
ÂĄ179.1m
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Receivables
ÂĄ2.5B
CAGR 3-Years
86%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accounts Receivables
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Receivables
ÂĄ3B
CAGR 3-Years
63%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Receivables
ÂĄ25.5B
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Receivables
ÂĄ206.1m
CAGR 3-Years
91%
CAGR 5-Years
87%
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
2.93 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Accounts Receivables?
Accounts Receivables
179.1m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Accounts Receivables amounts to 179.1m CNY.

What is CStone Pharmaceuticals's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
53%

Over the last year, the Accounts Receivables growth was -4%. The average annual Accounts Receivables growth rates for CStone Pharmaceuticals have been 53% over the past three years .

Back to Top